Song Y X, Peng Y, Qin C P, Xu T
Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Zhonghua Wai Ke Za Zhi. 2024 Nov 1;62(11):1058-1063. doi: 10.3760/cma.j.cn112139-20240814-00375.
Urothelial carcinoma (UC) is one of the most common malignant tumors. The development of omics technologies has provided new perspectives for the diagnosis and treatment of UC. Genomics, transcriptomics, and proteomics have unveiled the molecular mechanisms and biological characteristics of UC, which are conducive to the discovery of new therapeutic targets and biomarkers. Single-cell omics and spatial transcriptomics have further deepened the understanding of cellular heterogeneity and the tumor microenvironment. These technologies show great potential in molecular typing, non-invasive diagnosis, early screening, and personalized treatment of UC. This article, in response to the national key strategy, will delve into how omics technologies can drive new developments in the diagnosis and treatment of UC, as well as the application and translation prospects of these technologies in UC.
尿路上皮癌(UC)是最常见的恶性肿瘤之一。组学技术的发展为UC的诊断和治疗提供了新的视角。基因组学、转录组学和蛋白质组学揭示了UC的分子机制和生物学特性,有助于发现新的治疗靶点和生物标志物。单细胞组学和空间转录组学进一步加深了对细胞异质性和肿瘤微环境的理解。这些技术在UC的分子分型、非侵入性诊断、早期筛查和个性化治疗方面显示出巨大潜力。本文响应国家重点战略,将深入探讨组学技术如何推动UC诊断和治疗的新发展,以及这些技术在UC中的应用和转化前景。